Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 19
2003 11
2004 16
2005 19
2006 19
2007 35
2008 20
2009 14
2010 14
2011 28
2012 29
2013 18
2014 21
2015 22
2016 22
2017 24
2018 26
2019 38
2020 30
2021 40
2022 24
2023 16
2024 13
2025 8
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

472 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary fibrosis and type-17 immunity.
Senoo S, Higo H, Taniguchi A, Kiura K, Maeda Y, Miyahara N. Senoo S, et al. Among authors: kiura k. Respir Investig. 2023 Sep;61(5):553-562. doi: 10.1016/j.resinv.2023.05.005. Epub 2023 Jun 23. Respir Investig. 2023. PMID: 37356133 Review.
Molecular oncology of lung cancer.
Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S. Toyooka S, et al. Among authors: kiura k. Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37. doi: 10.1007/s11748-010-0743-3. Epub 2011 Aug 18. Gen Thorac Cardiovasc Surg. 2011. PMID: 21850578 Review.
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation.
Okawa S, Tomida S, Kuribayashi T, Nishimura J, Nakasuka T, Hirabae A, Hara N, Inoue H, Makimoto G, Ninomiya K, Rai K, Ichihara E, Hotta K, Tabata M, Maeda Y, Kiura K, Ohashi K. Okawa S, et al. Among authors: kiura k. Mol Cancer Ther. 2025 Nov 3;24(11):1763-1774. doi: 10.1158/1535-7163.MCT-25-0002. Mol Cancer Ther. 2025. PMID: 40439218
Managing Lung Cancer with Comorbid Interstitial Pneumonia.
Ichihara E, Miyahara N, Maeda Y, Kiura K. Ichihara E, et al. Among authors: kiura k. Intern Med. 2020 Jan 15;59(2):163-167. doi: 10.2169/internalmedicine.3481-19. Epub 2019 Sep 18. Intern Med. 2020. PMID: 31534086 Free PMC article. Review.
Chemotherapy for lung cancer: still alive!
Kiura K. Kiura K. Jpn J Clin Oncol. 2015 Jul;45(7):609-10. doi: 10.1093/jjco/hyv074. Epub 2015 May 19. Jpn J Clin Oncol. 2015. PMID: 25989990 No abstract available.
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancer.
Nishimura J, Kuribayashi T, Brägelmann J, Okawa S, Taoka M, Mori S, Nishimura T, Tanaka T, Makimoto G, Ninomiya K, Rai K, Ichihara E, Katayama R, Hotta K, Tabata M, Togashi Y, Maeda Y, Sos ML, Kiura K, Ohashi K. Nishimura J, et al. Among authors: kiura k. Mol Oncol. 2026 May 21. doi: 10.1002/1878-0261.70264. Online ahead of print. Mol Oncol. 2026. PMID: 42169500 Free article.
Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K, Fujimoto N, Kozuki T, Aoe K, Kiura K. Hotta K, et al. Among authors: kiura k. Expert Opin Biol Ther. 2020 Feb;20(2):109-114. doi: 10.1080/14712598.2020.1703945. Epub 2019 Dec 16. Expert Opin Biol Ther. 2020. PMID: 31825692 Review.
TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.
Kuribayashi T, Nishimura J, Okawa S, Taoka M, Mori S, Tanaka T, Nishimura T, Morita A, Hara N, Ninomiya K, Makimoto G, Rai K, Ichihara E, Hotta K, Togashi Y, Maeda Y, Kiura K, Ohashi K. Kuribayashi T, et al. Among authors: kiura k. Cancer Sci. 2026 May;117(5):1260-1272. doi: 10.1111/cas.70352. Epub 2026 Feb 27. Cancer Sci. 2026. PMID: 41757675 Free PMC article.
472 results